Author:
Garofolo Monia,Penno Giuseppe
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference10 articles.
1. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials;Baigent;Lancet,2022
2. Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling/autophagy hypothesis;Packer;Circulation,2022
3. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial;Kosiborod;Lancet Diabetes Endocrinol,2021
4. Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial;Lancet Diabetes Endocrinol,2023
5. Dapagliflozin and kidney outcomes in hospitalized patients with COVID-19 infection: an analysis of the DARE-19 randomized controlled trial;Heerspink;Clin J Am Soc Nephrol,2022